|Epigentek’s ‘Elegantly Accurate’ Epigenetic Services Provide Researchers with Tools for Accurate Data
|Epigentek, a biotech firm based in Farmingdale, New York, adds to its portfolio of specialized epigenetic research tools for scientists. The company recently announced the addition of epigenetic services to its repertoire of research aids, which ranges from research kits to sonicators, and they now provide the most comprehensive epigenetic services of all available service providers. Since 2005, Epigentek has designed and developed proprietary epigenetic research technologies and continues to contribute to the scientific community with services tailored specifically to epigenetic investigation.
The scientists and epigenetic experts at Epigentek provide personalized and affordable research projects designed and optimized for accuracy at every step of the workflow. Available services include genome-wide DNA methylation (5-mC) analysis, DNA hydroxymethylation (5-hmC) analysis, chromatin analysis, first-ever commercialized epigenetic-based drug discovery, bioinformatics, RNA analysis, and NGS sample preparation. High-throughput capabilities and next-generation sequencing is supported for nearly all epigenetic services offered.
Epigentek’s services for genome-wide DNA methylation (5-mC) analysis rely on highly specific and sensitive platforms. Services for DNA methylation analysis include bisulfite-based DNA methylation sequencing (Methyl-Seq), methylated DNA immunoprecipitation sequencing (MeDIP-Seq), methylation-specific PCR (MS-PCR) and global 5-mC quantification.
For chromatin analysis chromatin immunoprecipitation sequencing (ChIP-Seq), chromatin immunoprecipitation quantitative PCR (ChIP-qPCR), and antibody validation for ChIP is available.
Furthermore, Epigentek launched the first-ever commercialized epigenetic drug discovery services complete with extensive epigenetic targets. Their two screening assay systems – Epigenase™ for epigenetic enzyme inhibitor screening and EpiModifier™ for epigenetic histone modification profiling – enable drug candidates to be tested in situ and in vitro with a single dose for hits or multiple doses for half maximal inhibitory concentration (IC50s). Their epigenetic drug discovery services will help progress the development of targeted treatment options, especially cancer-related drugs.
Additional epigenetic services include genome-wide nucleosome positioning and CpG methylation, standalone DNA and chromatin shearing for optimal library construction, as well as DNA library preparation for ChIP-Seq, MeDIP-Seq, and Bisulfite-Seq.
The company’s complete epigenetic services portfolio contains a wide range of epigenetic analyses wholly customizable towards a researcher’s goals and interests. Various types of assays available include ELISA-based, PCR-based, and custom designed assays.
Epigentek’s comprehensive epigenetic services are optimized for accuracy at all steps of the workflow – from sample preparation to next-generation sequencing.
For detailed information on the epigenetic services offered, readers can visit http://www.epigentek.com/services
About Epigentek Group Inc.
Epigentek is a New York-based biotechnology company that focuses on developing and providing innovative technologies, services, and products as a complete and systematic solution for epigenetic related research and drug discovery. Visit the informative website at http://www.epigentek.com.